1-Siegel RL,
Miller KD,
Jemal A.
Cancer statistics,
2016.
CA Cancer J Clin 2016; 66: 7–30.
2-Govindan R,
Page N,
Morgensztern D,
et al.
Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance,
epidemiologic,
and end results database.
J Clin Oncol 2006; 24:4539–44.
3-Morgensztern D,
Ng SH,
Gao F,
et al.
Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey.
J Thorac Oncol 2010;5:29–33.
4-Masters GA,
Temin S,
Azzoli CG,
et al.
Systemic therapy for stage IV non-smallcell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
J Clin Oncol 2015; 33:3488–515.
5-D.
Hanahan,
R.A.
Weinberg,
Hallmarks of cancer: the next generation,
Cell 2011;144: 646–674.
6-D.S.
Chen,
B.A.
Irving,
F.S.
Hodi,
Molecular pathways: next-generation immunotherapy? inhibiting programmed death-ligand 1 and programmed death-1,
Clin.
Cancer Res.
2012;18:6580–6587.
7-H.
Borghaei,
L.
Paz-Ares,
L.
Horn,
et al.,
Nivolumab versus docetaxel in advanced nonsquamous non-Small-Cell lung cancer,
N.
Engl.
J.
Med.
2015; 373: 1627–1639.
8-J.
Brahmer,
K.L.
Reckamp,
P.
Baas,
et al.,
Nivolumab versus docetaxel in advanced squamous-Cell non-Small-Cell lung cancer,
N.
Engl.
J.
Med.
2015; 373:123–135.
9-R.S.
Herbst,
P.
Baas,
D.W.
Kim,
et al.,
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive,
advanced non-small-cell lung cancer: A randomised controlled trial,
Lancet 2016; 387: 1540–1550.
10-L.
Fehrenbacher,
A.
Spira,
M.
Ballinger,
et al.,
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre,
open-label,
phase 2 randomised controlled trial,
Lancet 2016; 387:1837–1846.
11-A.
Rittmeyer,
F.
Barlesi,
D.
Waterkamp,
et al.,
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3,
openlabel,
multicentre randomised controlled trial,
Lancet 2017; 389: 255–265.
12-FDA,
Adds Immunotherapy Approvals for Lung Cancer,
National Cancer Institute.
Natl.
Cancer Inst,
2017.
13-Nishino,
M.,
Hatabu,
H.,
Johnson,
B.E.,
and McLoud,
T.C. State of the art: response assessment in lung cancer in the era of genomic medicine. Radiology. 2014; 271: 6–27
14-Eisenhauer EA,
Therasse P,
Bogaerts J,
Schwartz LH,
Sargent D,
Ford R,
et al.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Eur J Cancer 2009;45: 228e47.
15-Wolchok JD,
Hoos A,
O’Day S,
Weber JS,
Hamid O,
Lebbe´ C,
et al.
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.
Clin Cancer Res 2009;15:7412e20.
16-Nishino M,
Giobbie-Hurder A,
Gargano M,
Suda M,
Ramaiya NH,
Hodi FS.
Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements.
Clin Cancer Res 2013;19:3936e43.
17-Nishino M.
Immune-related response evaluations during immunecheck-point inhibitor therapy: establishing a “common language” for the new arena of cancer treatment.
J Immunother Cancer 2016;4:30.
18-Seymour L,
Bogaerts J,
Perrone A,
Ford R,
Schwartz LH,
Mandrekar S,
et al.
iRECIST : guidelines for response criteria for use in trials testing immunotherapeutics.
Lancet Oncol 2017;18: el43ee152.
19-Strzelecki,
P.
Szczypinski,
A.
Materka,
A.
Klepaczko,
A software tool for automatic classification and segmentation of 2D/3D medical images,
Nuclear Instruments & Methods In Physics Research A,
2013;702:137-140
20-P.
Szczypinski,
M.
Strzelecki,
A Materka,
A.
Klepaczko,
MaZda-A software package for image texture analysis,
Computer Methods and Programs in Biomedicine 2009;94(1) :66-76
21-P.
Szczypinski,
M.
Strzelecki,
A.
Materka,
MaZda - a Software for Texture Analysis,
Proc.
of ISITC 2007,
November 23-23,
2007,
Republic of Korea:245-249
22-http://eco.iarc.fr/eucan
